Clinical trial
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
NCT00113308 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00113308 |
|---|---|
| Title | COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis |
| Official title | A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Arthritis, Rheumatoid |
| Intervention type | Drug |
| Interventions | GW406381 |
| Enrollment | 2,208 |
| Start date | Jun 1, 2005 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Jun 8, 2005 |
| Last update posted | Mar 14, 2017 |
| Countries | Argentina, Austria, Belgium, Bulgaria, Canada, Chile, Costa Rica, Denmark, Finland, France, Germany, Greece and 21 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: